The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial

The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial

BackgroundCurrently, there are no disease-modifying pharmacological treatment options for dementia with Lewy bodies (DLB). The hallmark of DLB is pathological alpha-synuclein (aS) deposition. There are growing amounts of data suggesting that reduced aS clearance is caused by failure in endolysosomal...

Full description

Bibliographic Details
Main Authors: Luiza Jadwiga Chwiszczuk, Monica Haraldseid Breitve, Bjørn-Eivind Bordewick Kirsebom, Per Selnes, John Chr. Fløvig, Anne-Brita Knapskog, Ragnhild E. Skogseth, Jessica Hubbers, Elin Holst-Larsen, Arvid Rongve
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Aging Neuroscience
Subjects:
DLB
dementia with Lewy bodies (DLB)
ambroxol
treatment
clinical trial in DLB
alpha-synuclein
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2023.1163184/full

Internet

https://www.frontiersin.org/articles/10.3389/fnagi.2023.1163184/full

Similar Items